InvestorsHub Logo


01/25/22 1:34 PM

#241326 RE: DewDiligence #241315

More from PRDS S-1 filing (p.97):

All employees currently work remotely. We intend to lease office space and labs in mid-2022.


01/28/22 10:09 AM

#241359 RE: DewDiligence #241315

(ENTA/PRDS/etc)—SRNE says its SARS-CoV-2 protease inhibitor won’t need ritonavir boosting:

SRNE could be a serious competitor. On the other hand, SRNE has a history of making big claims.